# Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia

> **NCT02914977** · PHASE1 · COMPLETED · sponsor: **Tara Lin** · enrollment: 18 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Daunorubicin

## Key facts

- **NCT ID:** NCT02914977
- **Lead sponsor:** Tara Lin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2019-04-03
- **Final completion:** 2021-07-15
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914977, "Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02914977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*